Nabuton Vp (Nabumetone)

Nabumetone is converted in the body to an active metabolite that non‑selectively blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition lowers prostaglandin production, which in turn diminishes inflammation, pain and fever at the site of tissue injury.

The specific dose and dosing schedule of Nabuton Vp are individualized by the prescribing clinician based on the patient’s condition, severity, age, renal and hepatic function, and other medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The pregnancy category for nabumetone is not clearly established, and safety data are limited. It should only be used during pregnancy or lactation if the potential benefit justifies the potential risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nabuton Vp. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nabumetone is a pro‑drug NSAID with a longer half‑life, allowing once‑daily dosing for many patients, whereas ibuprofen typically requires multiple daily doses. Both share similar COX inhibition profiles, but nabumetone may have a slightly lower incidence of gastrointestinal irritation in some studies, though individual response varies.

Nabuton Vp should be stored at room temperature, below 25 °C (77 °F). Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain product stability throughout its shelf life.

Nabuton Vp is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce occasional stomach upset. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

Serious risks include gastrointestinal ulceration or bleeding, severe liver injury, acute kidney impairment, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored for these events, especially if they have pre‑existing risk factors.

Nabuton Vp should be avoided in individuals with known hypersensitivity to nabumetone or other NSAIDs, active gastrointestinal ulcer or bleeding, severe hepatic or renal impairment, and in patients who have experienced serious cardiovascular events while using NSAIDs. A healthcare professional must evaluate suitability before prescribing.